GlobeNewswire: KYTHERA Biopharmaceuticals, Inc. Contains the last 10 of 69 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T08:59:05ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/09/22/770044/0/en/KYTHERA-R-Biopharmaceuticals-Submits-Investigational-New-Drug-Application-for-KYTH-105-to-Treat-Androgenetic-Alopecia-or-Male-Pattern-Hair-Loss.html?f=22&fvtc=4&fvtv=19158KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss2015-09-22T13:00:00Z<![CDATA[Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market]]>https://www.globenewswire.com/news-release/2015/08/18/761458/0/en/KYTHERA-R-Biopharmaceuticals-Submits-Marketing-Authorization-Application-in-the-European-Union-for-ATX-101-as-First-in-Class-Treatment-for-the-Reduction-of-Submental-Fat.html?f=22&fvtc=4&fvtv=19158KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat2015-08-18T13:00:00Z<![CDATA[Submission Supported by Four Pivotal Phase III Trials Conducted in Europe and North America With More Than 1,500 Patients Submission Supported by Four Pivotal Phase III Trials Conducted in Europe and North America With More Than 1,500 Patients]]>https://www.globenewswire.com/news-release/2015/08/06/758755/0/en/KYTHERA-Biopharmaceuticals-Releases-Second-Quarter-2015-Operating-Results-and-Progress-Update.html?f=22&fvtc=4&fvtv=19158KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update2015-08-06T20:05:00Z<![CDATA[Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection]]>https://www.globenewswire.com/news-release/2015/08/05/758019/0/en/Allergan-and-KYTHERA-Announce-That-Pending-Transaction-Will-Now-be-for-All-Cash-Consideration.html?f=22&fvtc=4&fvtv=19158Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration2015-08-05T12:00:00Z<![CDATA[DUBLIN, Ireland and WESTLAKE VILLAGE, Calif., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated their merger agreement with respect to Allergan’s pending acquisition of KYTHERA to provide for all-cash consideration to KYTHERA’s stockholders.  The agreement amends and restates the original merger agreement entered into by the parties on June 17, 2015, as amended on July 1, 2015.]]>https://www.globenewswire.com/news-release/2015/07/27/755379/0/en/Allergan-and-KYTHERA-Announce-Early-Termination-of-Hart-Scott-Rodino-Waiting-Period-for-Allergan-s-Pending-Acquisition-of-KYTHERA.html?f=22&fvtc=4&fvtv=19158Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA2015-07-27T21:45:00Z<![CDATA[DUBLIN, Ireland and WESTLAKE VILLAGE, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan’s pending acquisition of KYTHERA. ]]>https://www.globenewswire.com/news-release/2015/07/27/755247/0/en/KYTHERA-Biopharmaceuticals-Announces-Health-Canada-Authorization-of-BELKYRA-TM-a-Submental-Contouring-Injectable-Drug-i.html?f=22&fvtc=4&fvtv=19158KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i)2015-07-27T13:00:00Z<![CDATA[Recently Launched as KYBELLA(TM) in the U.S., BELKYRA(TM) Deoxycholic Acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or "Double Chin" Recently Launched as KYBELLA(TM) in the U.S., BELKYRA(TM) Deoxycholic Acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or "Double Chin"]]>https://www.globenewswire.com/news-release/2015/06/19/745915/0/en/KYTHERA-Biopharmaceuticals-Announces-US-Availability-of-KYBELLA-TM-First-FDA-Approved-Injectable-Treatment-for-Double-Chin-Through-KYBELLA-TM-Trained-Physicians.html?f=22&fvtc=4&fvtv=19158KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for “Double Chin” -- Through KYBELLA(TM) Trained Physicians2015-06-19T13:00:00Z<![CDATA[WESTLAKE VILLAGE, Calif., June 19, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced the U.S. availability of KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved non-surgical treatment for reduction of submental fullness, a common yet under-treated aesthetic condition also known as “double chin.” KYBELLA™ was approved in April by the U.S. Food and Drug Administration (FDA), and can now be purchased by physicians who have been trained on the safe use of KYBELLA™ and its approved indication.]]>https://www.globenewswire.com/news-release/2015/06/17/745244/0/en/Allergan-to-Acquire-KYTHERA-Biopharmaceuticals.html?f=22&fvtc=4&fvtv=19158Allergan to Acquire KYTHERA Biopharmaceuticals2015-06-17T11:00:00Z<![CDATA[– Complements Allergan’s Existing Position in Facial Aesthetics –]]>https://www.globenewswire.com/news-release/2015/06/17/745143/0/en/KYTHERA-Biopharmaceuticals-Grants-Stock-Options-Under-Inducement-Program.html?f=22&fvtc=4&fvtv=19158KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program2015-06-17T01:02:47Z<![CDATA[WESTLAKE VILLAGE, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase an aggregate of 15,000 shares of the Company’s common stock. The exercise prices were $54.66 for the June 12 option grants and $59.75 for the June 15 option grants, each of which was the closing trading price on the date of each grant. The stock options were granted pursuant to the Company’s 2014 Employment Commencement Incentive Plan, which was approved by the Company’s Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.]]>https://www.globenewswire.com/news-release/2015/06/06/742583/0/en/KYTHERA-Biopharmaceuticals-Grants-Stock-Options-Under-Inducement-Program.html?f=22&fvtc=4&fvtv=19158KYTHERA Biopharmaceuticals Grants Stock Options Under Inducement Program2015-06-06T01:40:00Z<![CDATA[WESTLAKE VILLAGE, Calif., June 05, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on June 2, 2015, the Compensation Committee of the Company’s Board of Directors granted 50 new employees options to purchase an aggregate of 252,000 shares of the Company’s common stock. The exercise price of each option was $53.26, the closing trading price on the date of grant. The stock options were granted pursuant to the Company’s 2014 Employment Commencement Incentive Plan, which was approved by the Company’s Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.]]>